I still think the method that Audion Therapeutics is doing trying to restore hearing loss is better than nothing.Reading FX-322's patent, it's clear there are some concerns with at least Novartis' method and it seems Audion, too:
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1="frequency+therapeutics"&OS="frequency+therapeutics"&RS="frequency+therapeutics"
The screenshot is of the most relevant part.
Overall, FX-322 seems to produce the same cell phenotype without depleting support cells. I'm a bit worried if the "hair cell like cells" produced by Audion by transducing support cells will function as well.
It's possible though that even a subpar signal (because who knows how relevant those differences clinically are) generated by these cells may help a lot with T but their trial is focusing on hearing loss and I don't think they will be nearly as strong as Frequency personally.
It's good how there are different companies trying to restore hearing loss and using different methods to achieve this.